After finishing at $8.41 in the prior trading day, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $7.79, down -7.37%. On the day, 4953800 shares were traded.
Ratios:
Our goal is to gain a better understanding of RXRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 04 ’24 when Gibson Christopher sold 40,000 shares for $9.02 per share. The transaction valued at 360,800 led to the insider holds 938,524 shares of the business.
Gibson Christopher sold 25,000 shares of RXRX for $225,500 on Apr 04 ’24. The Chief Executive Officer now owns 0 shares after completing the transaction at $9.02 per share. On Apr 03 ’24, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 40,000 shares for $8.84 each. As a result, the insider received 353,600 and left with 978,524 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 37.71 while its Price-to-Book (P/B) ratio in mrq is 3.93.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $16.75, while it has fallen to a 52-week low of $4.54.
Shares Statistics:
A total of 226.26M shares are outstanding, with a floating share count of 146.68M. Insiders hold about 32.04% of the company’s shares, while institutions hold 77.32% stake in the company.
Earnings Estimates
Its stock is currently analyzed by Lexicon Pharmaceuticals, Inc. different market analysts. The consensus estimate for the next quarter is $7.79, with high estimates of $28.25 and low estimates of $16.37.
Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
